Allergy Diagnostic & Clinical Research Unit, University of Cape Town Lung Institute, Cape Town, South Africa.
Allergy Asthma Immunol Res. 2010 Jan;2(1):1-13. doi: 10.4168/aair.2010.2.1.1. Epub 2009 Dec 30.
The diagnosis and management of asthma in young children is difficult, since there are many different wheezy phenotypes with varying underlying aetiologies and outcomes. This review discusses the different approaches to managing young children with wheezy illnesses presented in recently published global guidelines. Four major guidelines published since 2007 are considered. Helpful approaches are presented to assist the clinician to decide whether a clinical diagnosis of asthma can, or should be made in a young child with a recurrent wheezy illness and which treatments would be appropriate, dependent on risk factors, age of presentation, response to initial treatment and safety considerations. Each of the guidelines provide useful information for clinicians assessing young children with recurrent wheezy illnesses. There are differences in classification of the disease and treatment protocols. Although a firm diagnosis of asthma may only be made retrospectively in some cases and there are several effective guidelines to initiating treatment. Consistent review of the need for ongoing treatment with a particular pharmacological modality is essential, since many children with recurrent wheezing in infancy go into spontaneous remission. It is probable that newer biomarkers of airway inflammation will assist the clinician as to when to initiate and when to continue pharmacological treatment in the future.
儿童哮喘的诊断和管理具有一定难度,因为存在多种不同的喘息表型,其潜在病因和结局各异。本综述讨论了最近发表的全球指南中针对儿童喘息性疾病的管理方法。我们对自 2007 年以来发布的四项主要指南进行了评估。我们提出了一些有用的方法,以帮助临床医生判断在反复喘息的儿童中是否可以或应该做出哮喘的临床诊断,以及根据危险因素、发病年龄、初始治疗反应和安全性考虑,哪些治疗方法是合适的。对于评估反复喘息的儿童的临床医生来说,这些指南中的每一条都提供了有用的信息。在疾病分类和治疗方案上存在差异。虽然在某些情况下,可能只能回顾性地确定哮喘的确诊,并且有几种有效的治疗方案来启动治疗。因此,对于特定药物治疗方案的持续治疗需求进行持续评估是至关重要的,因为许多婴儿期反复喘息的儿童会自发缓解。未来,气道炎症的新型生物标志物可能会帮助临床医生确定何时启动以及何时继续药物治疗。